Nexstim Plc: Shares subscribed for based on Offer Warrant Plan 2019 have been registered

Written by Customer Service on . Posted in Public Companies.

Nexstim Plc: Shares subscribed for based on Offer Warrant Plan 2019 have been registeredCompany announcement, Helsinki, 8 November at 9 am (EET)Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announced on 6 November 2019 that an aggregate of 10,511,689 new shares of Nexstim were subscribed for based on the exercise of the Offer Warrants under the Warrant Plan 2019. Such new shares have today been registered with the Trade Register.Pursuant to the registration of the shares issued under Warrant Plan 2019 with the Trade Register, the number of shares in the Company is 45,912,562.The trading of the new shares registered will begin approximately on 11 November 2019 in Nasdaq First North Growth Market Finland and approximately on 12 November 2019 in Nasdaq First North Growth Market Sweden.NEXSTIM PLCMartin Jamieson, CEOFurther information is available on the website www.nexstim.com, or by contacting:Martin Jamieson, Chairman and CEO
 +44 771 516 3942
martin.jamieson@nexstim.comSisu Partners Oy (Certified Adviser)
 Jussi Majamaa
+ 358 40 842 4479
jussi.majamaa@sisupartners.comAbout Nexstim PlcNexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.For more information please visit www.nexstim.comAttachmentNexstim Company Announcement 11 Warrant shares registered_191108 E

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.